Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
18,350,252
-
Total 13F shares
-
3,312,096
-
Share change
-
+3,283,135
-
Total reported value
-
$12,386,145
-
Put/Call ratio
-
20%
-
Price per share
-
$3.74
-
Number of holders
-
46
-
Value change
-
+$12,277,831
-
Number of buys
-
45
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q1 2025
As of 31 Mar 2025,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,312,096 shares.
The largest 10 holders included
VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., Eversept Partners, LP, BlackRock, Inc., CITADEL ADVISORS LLC, JPMORGAN CHASE & CO, Catalio Capital Management, LP, T. Rowe Price Investment Management, Inc., Avidity Partners Management LP, and BANK OF AMERICA CORP /DE/.
This page lists
47
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.